Metastatic biliary tract carcinoma
Clinical trials for Metastatic biliary tract carcinoma explained in plain language.
Never miss a new study
Get alerted when new Metastatic biliary tract carcinoma trials appear
Sign up with your email to follow new studies for Metastatic biliary tract carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a Four-Drug cocktail outsmart bile duct cancer?
Disease control Recruiting nowThis phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…
Matched conditions: METASTATIC BILIARY TRACT CARCINOMA
Phase 2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug cocktail targets cancers missing key gene
Disease control Recruiting nowThis study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.
Matched conditions: METASTATIC BILIARY TRACT CARCINOMA
Phase 1/2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Matched conditions: METASTATIC BILIARY TRACT CARCINOMA
Phase 4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to boost bile duct cancer treatment
Disease control Recruiting nowThis early-phase trial tests a new drug called emavusertib added to standard chemotherapy and immunotherapy for people with untreated advanced bile duct cancer. The goal is to see if the combination is safe and to find the best dose. About 48 participants will be enrolled.
Matched conditions: METASTATIC BILIARY TRACT CARCINOMA
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC